Cargando…

Effect of a multispecies probiotic on inflammatory markers in critically ill patients: A randomized, double-blind, placebo-controlled trial

BACKGROUND: Impairment of intestinal barrier function and increased translocation of bacteria to the systemic blood flow contribute to the emergence of sepsis. Probiotics might be of beneficial effects on critically ill-patients, modulating intestinal barrier function and reducing inflammation. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanaie, Sarvin, Ebrahimi-Mameghani, Mehrangiz, Hamishehkar, Hadi, Mojtahedzadeh, Mojtaba, Mahmoodpoor, Ata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268190/
https://www.ncbi.nlm.nih.gov/pubmed/25535496
_version_ 1782349227241766912
author Sanaie, Sarvin
Ebrahimi-Mameghani, Mehrangiz
Hamishehkar, Hadi
Mojtahedzadeh, Mojtaba
Mahmoodpoor, Ata
author_facet Sanaie, Sarvin
Ebrahimi-Mameghani, Mehrangiz
Hamishehkar, Hadi
Mojtahedzadeh, Mojtaba
Mahmoodpoor, Ata
author_sort Sanaie, Sarvin
collection PubMed
description BACKGROUND: Impairment of intestinal barrier function and increased translocation of bacteria to the systemic blood flow contribute to the emergence of sepsis. Probiotics might be of beneficial effects on critically ill-patients, modulating intestinal barrier function and reducing inflammation. The aim of this trial was to determine the effect of probiotics on inflammatory markers in critically ill-patients in Intensive Care Unit (ICU). MATERIALS AND METHODS: This trial was conducted on 40 critically ill-patients admitted to the ICU. Patients were randomly assigned to receive placebo or probiotic containing Lactobacillus, Bifidobacterium and Streptococcus thermophilus (VSL#3) for 7 days. Acute Physiology and Chronic Health Evaluation (APACHE II) score Sequential Organ Failure Assessment (SOFA) and systemic concentrations of interleukin-6 (IL-6), procalcitonin (PCT) and protein C were measured before initiation of the study and on days 4 and 7. RESULTS: A significant difference in IL-6 (P = 0.003), PCT (P = 0.014) and protein C (P < 0.001) levels, and also APACHE II and SOFA scores (P < 0.001) was seen over the treatment period between two groups. Moreover, there was a significant decrease in serum IL-6 levels (from 211.85 ± 112.76 to 71.80 ± 28.41) (P < 0.001) and PCT levels (from 1.67 ± 1.27 to 0.47 ± 0.41) (P < 0.001) and a significant increase in serum protein C levels (from 7.47 ± 3.61 to 12.87 ± 3.63) (P < 0.001) in probiotic group during the study. CONCLUSION: Probiotics could reduce inflammation in critically ill-patients and might be considered as an adjunctive therapy in the treatment of critically ill-patients.
format Online
Article
Text
id pubmed-4268190
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-42681902014-12-22 Effect of a multispecies probiotic on inflammatory markers in critically ill patients: A randomized, double-blind, placebo-controlled trial Sanaie, Sarvin Ebrahimi-Mameghani, Mehrangiz Hamishehkar, Hadi Mojtahedzadeh, Mojtaba Mahmoodpoor, Ata J Res Med Sci Original Article BACKGROUND: Impairment of intestinal barrier function and increased translocation of bacteria to the systemic blood flow contribute to the emergence of sepsis. Probiotics might be of beneficial effects on critically ill-patients, modulating intestinal barrier function and reducing inflammation. The aim of this trial was to determine the effect of probiotics on inflammatory markers in critically ill-patients in Intensive Care Unit (ICU). MATERIALS AND METHODS: This trial was conducted on 40 critically ill-patients admitted to the ICU. Patients were randomly assigned to receive placebo or probiotic containing Lactobacillus, Bifidobacterium and Streptococcus thermophilus (VSL#3) for 7 days. Acute Physiology and Chronic Health Evaluation (APACHE II) score Sequential Organ Failure Assessment (SOFA) and systemic concentrations of interleukin-6 (IL-6), procalcitonin (PCT) and protein C were measured before initiation of the study and on days 4 and 7. RESULTS: A significant difference in IL-6 (P = 0.003), PCT (P = 0.014) and protein C (P < 0.001) levels, and also APACHE II and SOFA scores (P < 0.001) was seen over the treatment period between two groups. Moreover, there was a significant decrease in serum IL-6 levels (from 211.85 ± 112.76 to 71.80 ± 28.41) (P < 0.001) and PCT levels (from 1.67 ± 1.27 to 0.47 ± 0.41) (P < 0.001) and a significant increase in serum protein C levels (from 7.47 ± 3.61 to 12.87 ± 3.63) (P < 0.001) in probiotic group during the study. CONCLUSION: Probiotics could reduce inflammation in critically ill-patients and might be considered as an adjunctive therapy in the treatment of critically ill-patients. Medknow Publications & Media Pvt Ltd 2014-09 /pmc/articles/PMC4268190/ /pubmed/25535496 Text en Copyright: © Journal of Research in Medical Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Sanaie, Sarvin
Ebrahimi-Mameghani, Mehrangiz
Hamishehkar, Hadi
Mojtahedzadeh, Mojtaba
Mahmoodpoor, Ata
Effect of a multispecies probiotic on inflammatory markers in critically ill patients: A randomized, double-blind, placebo-controlled trial
title Effect of a multispecies probiotic on inflammatory markers in critically ill patients: A randomized, double-blind, placebo-controlled trial
title_full Effect of a multispecies probiotic on inflammatory markers in critically ill patients: A randomized, double-blind, placebo-controlled trial
title_fullStr Effect of a multispecies probiotic on inflammatory markers in critically ill patients: A randomized, double-blind, placebo-controlled trial
title_full_unstemmed Effect of a multispecies probiotic on inflammatory markers in critically ill patients: A randomized, double-blind, placebo-controlled trial
title_short Effect of a multispecies probiotic on inflammatory markers in critically ill patients: A randomized, double-blind, placebo-controlled trial
title_sort effect of a multispecies probiotic on inflammatory markers in critically ill patients: a randomized, double-blind, placebo-controlled trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268190/
https://www.ncbi.nlm.nih.gov/pubmed/25535496
work_keys_str_mv AT sanaiesarvin effectofamultispeciesprobioticoninflammatorymarkersincriticallyillpatientsarandomizeddoubleblindplacebocontrolledtrial
AT ebrahimimameghanimehrangiz effectofamultispeciesprobioticoninflammatorymarkersincriticallyillpatientsarandomizeddoubleblindplacebocontrolledtrial
AT hamishehkarhadi effectofamultispeciesprobioticoninflammatorymarkersincriticallyillpatientsarandomizeddoubleblindplacebocontrolledtrial
AT mojtahedzadehmojtaba effectofamultispeciesprobioticoninflammatorymarkersincriticallyillpatientsarandomizeddoubleblindplacebocontrolledtrial
AT mahmoodpoorata effectofamultispeciesprobioticoninflammatorymarkersincriticallyillpatientsarandomizeddoubleblindplacebocontrolledtrial